ArticleHuman vaccines & immunotherapeutics2025
Off-label use of recombinant adjuvanted Herpes Zoster vaccine in a 10-year-old high-risk patient affected by epidermolysis bullosa: A case report.
Article in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epidermolysis bullosa is a rare genetic disorder characterized by skin fragility and blistering, resulting from mutations in dermal-epidermal junction structural proteins. Disease severity varies, with some cases involving extensive skin damage and complications secondary to chronic inflammation. Patients with immune-mediated dermatological conditions face a heightened risk of Herpes Zoster and Post-Herpetic Neuralgia, particularly during immunosuppressive treatments. A 10-year-old female with Recessive Dystrophic Epidermolysis Bullosa received off-label Recombinant adjuvanted Zoster Vaccine (RZV) - approved in individuals 18 years of age and older - before initiating Janus kinase inhibitor therapy, required to manage the underlying condition. Two standard RZV doses were administered on February 22 and April 29, 2024. No immediate vital sign alterations nor Adverse Events Following Immunization were documented in the first 7 days after immunization. A 6-month follow-up revealed no relevant emergent clinical events nor Herpes Zoster episodes. In conclusion, the case offers preliminary insights into RZV safety for high-risk pediatric patients. However, robust safety and efficacy studies are warranted to support the implementation of RZV for vulnerable individuals under 18 years of age.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.